0001562180-19-004216.txt : 20190808
0001562180-19-004216.hdr.sgml : 20190808
20190808163856
ACCESSION NUMBER: 0001562180-19-004216
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190806
FILED AS OF DATE: 20190808
DATE AS OF CHANGE: 20190808
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Beddingfield III Frederick
CENTRAL INDEX KEY: 0001573074
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38155
FILM NUMBER: 191010130
MAIL ADDRESS:
STREET 1: C/O KYTHERA BIOPHARMACEUTICALS, INC.
STREET 2: 27200 WEST AGOURA ROAD, SUITE 200
CITY: CALABASAS
STATE: CA
ZIP: 91301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sienna Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001656328
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273364627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD, SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
BUSINESS PHONE: (818) 629-2256
MAIL ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD, SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
FORMER COMPANY:
FORMER CONFORMED NAME: Sienna Labs, Inc.
DATE OF NAME CHANGE: 20151020
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2019-08-06
false
0001656328
Sienna Biopharmaceuticals, Inc.
SNNA
0001573074
Beddingfield III Frederick
C/O SIENNA BIOPHARMACEUTICALS, INC.
30699 RUSSELL RANCH ROAD, SUITE 140
WESTLAKE VILLAGE
CA
91362
true
true
false
false
President & CEO
Common Stock
2019-08-06
4
A
false
150000.00
A
967599.00
D
Common Stock
112614.00
I
See Footnote
Stock Options (Right to buy)
15.08
2019-08-06
4
D
false
190910.00
D
2028-06-01
Common Stock
190910.00
0.00
D
Stock Options (Right to buy)
15.00
2019-08-06
4
D
false
42590.00
D
2027-07-26
Common Stock
42590.00
0.00
D
Stock Options (Right to buy)
2.32
2019-08-06
4
D
false
40968.00
D
2019-01-01
2029-01-01
Common Stock
40968.00
0.00
D
Stock Options (Right to buy)
2.32
2019-08-06
4
D
false
93750.00
D
2029-01-01
Common Stock
93750.00
0.00
D
Stock Options (Right to buy)
2.32
2019-08-06
4
D
false
93750.00
D
2029-01-01
Common Stock
93750.00
0.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
42590.00
A
2027-07-26
Common Stock
42590.00
42590.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
190910.00
A
2028-06-01
Common Stock
190910.00
190910.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
40968.00
A
2019-01-01
2029-01-01
Common Stock
40968.00
40968.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
93750.00
A
2029-01-01
Common Stock
93750.00
93750.00
D
Stock Options (Right to buy)
0.71
2019-08-06
4
A
false
93750.00
A
2029-01-01
Common Stock
93750.00
93750.00
D
Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
Includes a total of 5,916 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
The shares are directly held by the Beddingfield Family Trust.
The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options.
Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Timothy K. Andrews, attorney-in-fact for Frederick C. Beddingfield III
2019-08-08